Oil Drops As Iran Responds… Plus Novo Nordisk Cuts Ties With Hims & Hers 6/23/25

23 Jun 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Notes: CNBC's "Fast Money" - Episode Summary (6/23/25)

Episode Overview

  • Title: Oil Drops As Iran Responds… Plus Novo Nordisk Cuts Ties With Hims & Hers
  • Host: Melissa Lee
  • Panelists: Tim Seymour, Dan Nathan, Guy Adami, Julie Beal
  • Key Topics: Oil market reactions to geopolitical tensions, Novo Nordisk's partnership cut, stock performances of various companies.

---

Market Reactions to Geopolitical Events Key Events

  • Iran's Missile Strike: Iran targeted a U.S. base in Qatar with 14 missiles, which were countered, resulting in no casualties.
  • Oil Prices: Brent crude oil dropped over 7%, WTI also fell sharply, with market analysts discussing the implications of these geopolitical maneuvers.

Market Sentiment

  • Initial Reactions: Major indices dipped but recovered towards session highs, indicating a relief rally.
  • Investor Sentiment: Markets appeared to underprice the risks associated with the ongoing conflict in the Middle East.

Insights from Experts

  • Matt Gertkin, Chief Geopolitical Strategist at BCA:
  • Skepticism regarding the situation in the Middle East, suggesting tensions are likely to continue.
  • Concern over Israel's continued aggressive posture towards Iran.

---

Novo Nordisk's Strategic Moves Partnership Termination

  • Cutting Ties with Hims & Hers: Novo Nordisk ended its direct-to-consumer partnership over concerns about Hims' promotion practices.
  • Stock Impact: Novo's shares fell by 5.5%, while Hims & Hers dropped 34%, marking its worst trading day.

Market Implications

  • Weight Loss Drug Landscape: Discussion surrounding the competitive dynamics in the weight loss drug market, especially against Eli Lilly.
  • Trial Data Updates: Analysis of Novo's new weight loss medications and their comparative efficacy.

---

Sector Performance Insights KB Home Earnings Report

  • Earnings Results: KB Home's stock dropped despite beating earnings estimates.
  • Market Reaction: Guidance for the upcoming year was lower than expected, leading to negative sentiment.

Tesla’s Robo-Taxi Rollout

  • Market Reaction: Tesla shares surged after the rollout of its robo-taxi service in Austin, Texas.
  • Future Projections: Discussion on how the success of Tesla's autonomous vehicles could reshape its revenue model.

Lululemon's Decline

  • Stock Performance: Shares hit five-year lows amid concerns over U.S. growth and competitive pressures.
  • Market Examination: Panelists debated the reasons behind the decline and future recovery potential.

---

Key Takeaways

  • Geopolitical Tensions: Investors are cautiously optimistic despite ongoing Middle Eastern tensions, reflected in market recovery.
  • Novo Nordisk's Challenges: The company faces pressure in the weight loss drug market, compounded by a failed partnership.
  • Sector Volatility: The housing market and retail sectors are experiencing significant fluctuations in stock performance, signaling broader economic concerns.
  • Tech and Innovation: Tesla's advancements in autonomous vehicles are viewed as critical to its future profitability, though the timeline for significant revenue impact remains uncertain.

---

Final Thoughts

  • The panel emphasized the complexities of market reactions to geopolitical events and the importance of monitoring economic indicators that could signal shifts in investor sentiment.
  • Moving forward, attention will be on how these companies adapt to their respective challenges, particularly in volatile markets.

---

Disclaimer *The opinions expressed in this summary are solely those of the podcast participants and do not reflect the views of CNBC or its affiliates.*

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live from the Nasdaq Market Site in the heart of New York City's Times Square. This is Fast GobiMaker dropping on its latest trial results. And data on Amgen's weight loss candidate sending those shares lower too. The latest on the space and how to play the stocks right now. Plus, KB Home shares dropping after its latest earnings report. Tesla's long-awaited robo-taxi rollout sparks a rally. And Lululemon shares trading at five-plus-year lows. What is behind this move and can the company recover? I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Dan Nathan, Guy Adami, and Julie Beal.

0:47We start off with markets seeming to breathe a sigh of relief. even as the U.S. enters the war between Israel and Iran. While major averages dipped on news, Iran had targeted U.S. assets in Qatar. They reversed course as damage looked to be contained and ended the day near their highs of the session. Oil prices, meantime, dropping, with Brent crude settling down more than 7 percent. WTI crude also sharply lower as Iran avoided any action in the Strait of Hormuz. Volatility also down. The VIX briefly hitting its highest level in a month before retreating. But Treasuries did catch a bit with the yield in the 10-year, hitting its lowest since early May.

1:21For the latest on the U.S. involvement in the Middle East, let's get to Megan Casella in D.C. Megan. Melissa, this was Iran's official retaliation against the U.S.'s strikes over the weekend. The Iranians fired 14 short and long-range missiles at Al-Udid, the U.S.-run airbase in Qatar. All of those missiles were effectively countered, and there were no deaths or injuries reported as a result of the attacks. Two U.S. Defense Department officials also say there was no damage done to the base itself. Just in the last hour now, President Trump made his first remarks on the strikes. He called it a very weak response, which we expected and have very effectively countered.

1:57He went on to thank Iran for giving us early notice. And he ended with, quote, perhaps Iran can now proceed to peace and harmony in the region. And I will enthusiastically encourage Israel to do the same. So a couple of things there, the president confirming that the Iranians gave the U.S. a heads up in advance of the attacks, making that more of a strategic move that may have made these attacks more symbolic than anything else, a way for Iran to sort of retaliate without doing the type of damage that would have provoked the U.S. even further. The president also here urging an end now to the conflict, a return to peace and harmony.

2:31And the White House today has said that it is still committed to a diplomatic solution. So the question from here, Melissa, is whether Iran and Israel are committed to that solution as well. All right, Megan, thank you. Megan Casella in Washington for us for more on how markets reacted to hopes for de-escalation. Let's bring in Matt Gertkin, chief geopolitical strategist at BCA, an independent research firm. Matt, great to have you with us. Are markets underpricing what is going on in the Middle East, or have we seen the worst of this conflict for now? Well, thanks very much, Melissa. It's not clear that we've seen the worst.

3:05I would be quite skeptical. These are major events building up from structural tensions in the region and in Iran and between Iran and Israel. We've had generational change in the leadership across several of the Gulf Arab states, and we see that happening in some other Western countries. But there has not been a generational change in the Iranian regime or in Israel, for that matter. And so we're still seeing hardline and hawkish leaders. Israel now will be front and center. The U.S. president will have to put some pressure on them and really discipline Israel to ensure that this doesn't escalate any further.

3:40And I'm not convinced that will happen. I think, in fact, Israel will continue to fight the fight, and that could very well provoke Iran to take more actions. Hey, Matt, peace and harmony, that's not something that's existed in the Middle East probably in thousands of years. So when the president of the United States suggests this, what you just said about Israel, I don't know how Israel comes to term with a major tenant of the Iranian government's view about Israel, is the death to Israel. So we're probably a ways off from peace and harmony, wouldn't you suggest? Well, there's got to be a damage assessment, you know, of what's actually happened.

4:14If Israel is satisfied that Iran is permanently off the path of a nuclear weapon, then they could probably listen to the president and say, OK, it's time to shift to negotiations. But the truth is, the Iranians have taken the approach that they can weather the storm. They can sustain really severe attacks. They've moved around the enriched uranium. They've got the same regime in place that they think can survive and can suppress social unrest that will probably stem from these attacks ultimately. And so that means that we'll have a regime that's much more hardened in its conviction. It'll still have some of the intelligence and talent necessary, and it'll still be getting help over the years from Russia and China.

4:54So there will, from Israel's point of view, there's still a very good reason to continue to press against critical infrastructure, undermine this regime and keep the Americans entangled. Matt, the move in Kouradol suggests today's retaliation maybe takes closing the straits off the table. Do you believe that or is that sort of a little bit getting ahead of ourselves? It's getting ahead of ourselves. It's not entirely off the table. Closing the Strait of Hormuz was always something that would only happen if the Iranians were convinced that the regime was absolutely going down and they had no other choice.

5:28But that could still happen if we had a series of bad events and a downward spiral. What that requires is effectively the way that would play out. Either the Iranians were faking it today and they're about to retaliate in a bigger way, or Israel could strike some of their own capacities. For example, Israel could strike their ability to export oil abroad, and then they would start to retaliate against regional oil infrastructure, and the U.S. would get involved and things could escalate from there. Or just the lack of trust between the U.S. and Iran. If at any point the Iranians look like they might make a move to mine the strait or take out some ships, or if the Americans look like they might try to preempt Iran and remove their ability to do that, then it could cause those itchy trigger fingers to move and we could end up with a crisis that was a miscalculation.

6:15So there's several ways in which this could still be on the table. But it is admittedly a lower probability now than it was, you know, just a day ago. Hey, Matt, so, Tim, as therefore as a geopolitical strategist, what is either your highest probability negative major vol event out there? What aren't we thinking about? I understand that this is a complex geopolitical dynamic. But again, and and maybe maybe this is the wrong day to be looking at other parts of the world. But but where are you most concerned? Because right now this looks like it could have been a bad situation that that at least as of the end of the day, the VIX is down.

6:50Volatility is lower. Markets went higher. Yeah, it's extraordinary what's happened today. But we have to realize it's an issue of time. You know, what I've charted for three years is this destabilization of the Middle East. The Middle East was not able to produce its own balance of power. It really. And that's that's the norm. perennial, but the Americans need to get involved and be the actor that arbitrates and fixes a balance of power that usually is pretty precarious anyway. And when you're living through these kind of sequences, there's a fog of war, things change on a daily basis, the market mood shifts really rapidly.

7:27What we know is that Israel is determined to deal a really significant blow to this regime that could ultimately make it very hard for the regime to survive because of social unrest stemming from their sclerotic economy, which will now be weakened. And we also know the Iranians are intending to survive and build back better in a way that would perpetuate the conflict, and we know that the U.S. will intervene. So I think what that tells us is we're not having a deal in the Middle East that unleashes Iranian reserves and creates peace and stability and a balance of power. We're still in an unstable environment.

8:04And over a period of months, that could continue to influence the markets in a way that would that would cause a risk premium in the oil price and would help to foment some of the fears of stagflation. Matt, great having you on. Thank you for your insights today. Matt Gertkin. Thank you very much. of BCA. We want to have somebody like Matt on because you're trying to figure out what exactly are we not thinking of in terms of the market action. Why are we higher? Why is vol down? All these things that you wouldn't have thought we play that game. If I told you what had happened, would you be able to tell me what the reaction of the market is?

8:36100 percent, no. None of this today I would gamble. Maybe yields lower. It was the only one I potentially could have gotten right based on. But in terms of crude oil being down 6 percent, absolutely not. The S &P rallying the way it did, No, given what we heard on Friday into Saturday or into Sunday. No. So that's why it becomes such a difficult game to play. And what aren't we talking about? To me, listen, loss of life is a horrible thing. I think we're all very respectful of that. But the market moving event, in my opinion, is closing the straights. And if that were to happen, then we'll have a conversation about where does crude go, where does the S &P go.

9:08But short of that, in terms of the market, it's sort of business as usual. Yeah. Julie Beal, your thoughts? because most market strategists do say unless oil jumps, unless there is some sort of event that really causes a jump in Brent, a jump in WTI, et cetera, and hurts the pocketbooks of everyday Americans, we're not going to see a market impact. Yeah, I think that's probably right. I think everyone is very, very focused on where oil is moving because it's been such a good guy for inflation. It's been so helpful in order for us to kind of move forward to a regime where we can lower interest rates.

9:39And I think if that is taken off the table, that really jeopardizes is both what the path for the Fed is, but it also, I think, it's going to really take a bite out of consumer confidence. And that's what really a lot of our economy is hinging on right now. What I think is interesting is just, it really feels like in this market is like, oh, okay, this wasn't as bad as we were all worried about. We can manage through this level of uncertainty. It's fine. And I agree. I think we still haven't really cleared through enough to know how exactly it's going to impact us over the longer term. And we are so close to getting that first cut, right?

10:14I mean, we heard Bowman today following up on Waller on Friday. I think we learned today, and we didn't learn it. We were reminded today that the Fed is so much more important than any other factor out there. And that this is a Fed that I think, after Powell, one of the observations was this is a Fed that, huh, seems to be okay with PCE at 3.1%. And that said, actually, until the labor market falls apart, we're kind of comfortable here. But, you know, even without the labor market falling apart, you've had two important voices, including vice chair today Bowman, basically saying she saw July could be a possibility.

10:48Markets are looking through war right now. They are looking at the Fed. And if you look at some of the performance of the market today, you even had small caps outperforming. You had some equal weighted stuff outperforming. It wasn't just a runaway for the tech growth trade. It really was stuff that would benefit from the Fed stepping in and finally moving, which may or may not happen. But that's the more important headline out of today. Yeah, I go back six months, right? So we've had really two bouts of major volatility in the stock market. That was December 18th after the Fed, you know, I guess Fed Chair Powell came out a bit more hawkish than some folks felt going into 2025.

11:23And that was actually a really interesting day, if you think about it, because I don't think that caught anybody by a huge surprise. It just pushed out rate cuts, you know, maybe six to nine months or something like that. So here we are now. Nothing that the Fed said really moves the stock market. Just think about that over the next or the last few months or so. And obviously, Fed Chair Powell speaks tomorrow. Last week, he was concerned about a lot of the things we're talking about, the uncertainty around geopolitical, the uncertainty about inflation. And you look at a day like today and you say to yourself, there's no concern.

11:52I mean, like there's absolutely no concern. People are looking past geopolitics. They're looking past inflation. They're looking past a trade war. And that was the other bout of technology or about volatility, I was going to say, just two months ago. But I'm not clear. Are you saying that you think that the Fed's influence now on the market in terms of being a catalyst is not significant? I think it's less significant. I think to your point, once you start having this chorus of folks suggesting that rate cuts are going to come sooner than a lot of folks think, and then maybe there's more of them this year.

12:20I mean, I think it's amazing. We go back to September last year. They started with a 50 basis point cut because they were worried about the jobs market. Then they followed up with two more. Now, if you're telling me if PC comes in cooler, PC, if some of the stuff in and around geopolitics kind of settles down a little bit and inflation and growth and all this stuff, maybe they're too low on growth, too. I mean, the way they kind of locked it lower last week. So, again, I can see why folks are starting to think about cuts sooner than some might expect. In terms of yields, again, I get it. They're lower today.

12:50It makes sense. I'm still probably one of the few people out there that can think yields can go higher by the end of the year. When I say higher, I think we can approach 5%. And I don't think it's going to be because growth is so robust. I think it's all the concerns we've had. But, by the way, the market doesn't seem to care about at all. But if you do get a hiccup in the bond market, whether it's over the next couple of months or early next year, I mean, at some point the market absolutely has to care, at least. We've got a news alert on Starbucks. Kate Rogers has got the details. She joins us on the FastLine.

13:18Kate? Hey, Melissa. So we're getting some headlines from Chinese media Kate Shin that says Starbucks is considering a full sale of its China operations, and that's a significant shift in strategy for the company. The report cites some people familiar with the matter, saying that the company's held preliminary talks with more than a dozen potential acquirers, including private equity firms, Hill House Capital Groups, FountainVest Partners, and TrueStar Capital. Now, CEO Brian Nichol told the Financial Times in recent weeks of the Chinese brand here, Starbucks China, people see value in the Starbucks brand.

13:53They see the coffee category growing. And I think that they'd love to be partnering up with us and figuring out how we take this from 8 ,000 to 20 ,000 stores. And just a reminder on Starbucks China, it's second home market, Melissa. They're looking to have about 9 ,000 locations there by 2025. And that market has seen many challenges as of late due to a softer consumer environment and, of course, the expansion of lower-cost competitors like Luckin Coffee. Same store sales were flat in China last quarter, and they've been discounting drinks that are non-coffee-based because the consumer in China is more focused on those tea options.

14:27And they've talked about exploring these strategic options for the China business, but there have been very few details about the plan beyond that. So once again, we're getting these reports from Chinese media reporting the company considering that full sale of the business. We're out to Starbucks for comment and more to come when we get it. But you can see the stock is slightly higher on this news headline. Back over to you. Kate, thank you. Kate Rogers. Tim Seymour, is this short sighted or is this a good move? I think it's potentially thoughtful. I do think this is a company that if it was four years ago, we were seeing this headline, this stock would be down 20 percent.

15:02I think we've digested a lot of pain. And I think we you know, when we talk about a turnaround at Starbucks, we don't talk We're not talking about a company that's necessarily broken. We are talking about operational improvements, but we are talking about, again, Brian Nickel. He's a marketing guru. And part of what I think is the turnaround in Starbucks is getting the U.S. market back to where it was. So not a great headline, but the stock seems to not care. Yeah. Julie, you think it's a better Starbucks without the China operations? It's been really, really challenging for them to find the growth that they've been looking for and be competitive.

15:34You know, a lot of it is based on the premise that this economy is going to move from one that's about production to one that's about consumption. We haven't really seen that, but we have seen lower priced peers really, really make it difficult for Starbucks to be successful. And I think it ends up being a distraction because I think it's a very different business in China than it is in the U.S. And what really, really needs to be solved is the domestic business. That's really the problem right now. Yeah, there was a time, though, where a big part of Starbucks premium had to do with the expected growth in China.

16:05A lot of these brands premium had to do with China. But do you guys remember, like we were talking about this Luckin Coffee. This was the Chinese brand, and I think Kate just mentioned it. I'm starting to see stores popping up here in the United States again, which is really interesting to me. Now, obviously, that was a big financial fraud. If you go back, I want to say five or six years or so. But again, I mean, Starbucks seems like they have multiple flanks they have to defend right now. And whether this marketing guru can fix it or not is another story. But if you think about nationalistic tendencies, you know, going on amongst Chinese citizens, and it's probably only likely to accelerate, in my opinion, this could be a way to kind of get out of this business, take a little something, refocus on North America or the rest of the Western world.

16:45CMG fix was, I think, a little bit easier than the Starbucks fix. And one of the problems that I don't think anybody can fix is evaluation, which I think at 31 times is probably a little expensive, not historically expensive. But their growth trajectory in 2025 makes it expensive. No, I just I think that the multiple is probably the place where we should start. It's not cheap. And all the oat milk you drink in your coffees, guy, isn't going to change that. They really should charge extra. Well, they do charge me extra. And I'm more than happy to pay it. Oat milk's a very important staple of my diet, Melissa.

17:16And it does wonders for my constitution. Your system. Let's get to cybersecurity stocks jumping today amid the threat of potential cyber attacks from Iran. CrowdStrike hitting an all-time high, up more than 3 percent. Fortinet, Zscaler, Palo Alto Network is also climbing today. We are on high alert in terms of hits to the infrastructure, et cetera. After, if we think that the only retaliation Iran was going to wage were those missiles, we might want to rethink that because everything is on the table at this point. I think every period of weakness or idiosyncratic event that the sector is seeing, whether it's CrowdStrike, obviously, and their upgrade and their update, I should say, they created havoc and mayhem and fines and whatnot.

17:58It's been a time to buy cybersecurity and buy CrowdStrike, which is my favorite of the bunch. It's not cheap, but that is north of 30 percent growth that I'm paying for. Palo Alto is where I would go. Not cheap. Fifty-four times next year's numbers probably deserves it because I do think it's the best in class. But, you know, the secular shift into these names has been going on for more than five or six years now. Rightly so. This just adds to the reasons why you want to own them. Coming up, Lulu Lowe's shares the athletic wear maker hitting their worst level in more than five years. What this company needs to do to get shares back off the mat.

18:34But first, we're watching shares of KB Home after its latest earnings report. The details and numbers from the quarter. Next, do not go anywhere. Fast Wendy's back in two.

18:49Welcome back to Fast Money. We've got an earnings alert on KB Home, the stock dropping after hours despite the company beating both earnings and revenue estimates. CNBC's Diana Olek has got more. Diana. And Melissa, that weakness is likely because full year guidance was lighter than expected and homes delivered decreased 11 percent year over year. CEO Jeff Metzger said in the release, though market conditions have softened, we remain consistent in our focus on optimizing our assets to offer the most compelling value to our buyers, maintaining pricing transparency and enhancing margins and returns.

19:20Now, the company's housing gross profit margin was 19.7 % compared to 21.2 % the year before due to price reductions and other homebuyer concessions, higher relative land costs, geographic mix and reduced operating leverage, partly offset by lower construction costs. Now, that average selling price did increase slightly to$488 ,700, but But that's likely skewed due to more activity on the higher end as lower income buyers drop out. So they lower the prices a little, but higher end buyers. You get it, Melissa? Yeah. All right. Diana, thank you. Diana Olek. Another disappointment out of KP Home.

19:56It should be lower. I mean, and again, I think we've done a decent job with the home builders. But you look at the numbers. I mean, earnings were down 11 percent year over year. Deliveries were down 11 percent year over year. And new orders were down 13 percent year over year. And obviously they guided lower. And this is on top of other guides that have been lower. It comes down to affordability. And if you look, I mean, things are changing. And if you ever see an uptick in the unemployment rate, which, again, I think we will see. I'm surprised we haven't gotten there. The homebuilders, you don't go near them here.

20:24Let's even say that there is a cut in July, Julie, that I would imagine that's probably not enough to help these guys in terms of buying down those mortgages. I don't think so, right? And the big challenge to them too is that their inventories are up 11 % year over year. So now they have this inventory they can't sell. They have no pricing power. And even if we get a 25, even if we get a 50 basis point rate cut, right? Mortgage rates are still quite high. And there is a limit to how much they can buy down, right? Because I think people are starting to really recognize and internalize that we're probably never going to see 2.5%, 3 % mortgages again.

21:03And I think that that changes the dynamic where you're saying, OK, fine, you can buy down my interest rate for a year or two, but eventually everything is going to come back down. If it can't come back down, that changes the affordability question over the long term in a really meaningful way. But in terms of affordability of the stock, it's not expensive. And if I look at it relative to itself over a five year, it's about 5 % cheap over a 10 year. It's probably 20 % cheap to where it trades. And it's got almost a 10 % free cash flow yield. I don't like home builders. I haven't liked them for a while, but I do think sentiment isn't great, and I do think the stock's not expensive, and I think it's something you should be keeping an eye on.

21:40I mean, in theory, guys, shouldn't the stock turn before we see interest rates? And, you know, you've had Vinny and Porter and Danny Moses talks about the homebuilders, and they do turn six to nine months before. I just don't think we're there yet, and especially if you haven't seen the unemployment rate move to where I think it's going. I think this is more about the employment picture than it is about the interest rate picture. All right. There's a lot more Fast Money to come. Here's what's coming up next. Lululemon goes even deeper into downward dog, the stock hitting its lowest level since the pandemic.

22:14Will that slide continue or can shares bounce back? We'll debate. And it's not just retail. Novo Nordisk heading sharply lower as well. the latest data hitting that name, and why it's cutting ties with him and hers on their weight loss drug deal. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.

Read the full transcript

22:46Welcome back to Fast Money. Shares of Lululemon continuing to slide. The stock heading its lowest level in more than five years. Lulu now down more than 33 percent since cutting its full year earnings guidance about two weeks ago. CEO Calvin McDonald saying on that earnings call that he is not happy with U.S. growth and cited a cautious consumer. Tim, you pointed this out on our earlier call today. Because I think you've got two forces that are working against them. One is the fact that they have this intense competitive landscape. They have margins that are facing that I think are confronting them and they went into this downward spiral and it really has been a spiral.

23:20Stock's, I don't know, it's down 46 percent off its 52 week high. And it did it also at a time when I think there's cyclicality for athleisure. I just think there are trends here. And whether you're looking at Deckers, whether you're looking at some of the other high profile apparel or footwear names, I think it's an issue. And again, you get back to valuations in this name. And I think they mean almost nothing at this point because it is trading 50 percent cheap to where it was on a five year. It's trading 60 percent cheap to where it was on a 10 year. And that to me doesn't mean anything. Specialty retail.

23:53You know, again, Jeff Mack used to say it's where hope goes to die. And we are on the other side of that now. And it happens. Listen, you look at what happened to Under Armour. I mean, it happens to all these companies. They have these tremendous growth arcs. They dominate the space. They're leaders. They're the innovators. Competition comes in. They rest on their laurels, and everything goes away seemingly overnight, and that's what's happened here. But you are still wearing Loon stuff to your yoga classes, right? No, my boxer briefs are fantastic. You go to hot yoga, right? He's a hot yoga. Tell the folks your favorite yoga position.

24:24Really quickly, though, Tim. Tim doesn't want me to tell you. Tim, really quickly, your view. So haven't the guidance been cut a few quarters in a row? They're still expecting single-digit, mid - to high-single-digit earnings and sales growth 15 times. You know what I mean? At some point, these guys also get their stuff together, and they turn it around at some point. I think that I'm more worried about, for a lot of these names, the cyclicality in the space. I think the consumer is tapped. Other than guy who needs 16 pairs of yoga pants, I think most people do not. The leggings. Yeah, the leggings.

24:56And that belt that you wear. Isn't that a belt that goes along with that? You're saying that like you're trying to make fun of me, like I'm somehow supposed to be. No, we're saying it as a matter of fact. I mean, I'm very proud of my leggings. And my boxer briefs, very comfortable, by the way. She might. Just to keep this on a tray, Julie, a Nike or a Lulu? Because you could make a lot of the same arguments for Nike. Yeah, it's a woof for both, honestly. That's a tough choice because I think a big problem that I see with Lululemon is that when they identified at their investor day, you know, what they need to do to get their act together, a lot of it is resting on innovation.

25:32And my challenge is that I think there's a lot of opportunity for innovation in shoes and footwear. Leggings, it's a little bit harder for me to see how innovation is going to dig them out of this hole, especially if we do see kind of a cyclical shift away from athleisure. Nike, I think you can make a better argument for there being a real opportunity for them in terms of innovation and stores. The productivity that a Lululemon store has is still very high. So there's not a ton that lets it, you know, stay there. It can go down quite a bit. The operating margins can contract. So I think that the valuation of 15 times is cheap, but that assumes that we have a good, solid hold on earnings, and I don't think we have that here.

26:14All right. Coming up, shedding pounds and partnerships by Novo Nordisk is cutting ties with Kim's and Hers on their weight loss drug deal and the latest data hitting the pharma stock. The details when Fast Money returns.

26:32Stick around. What else would it be? I mean, welcome back to Fast Money. Stocks climbing is Iran's retaliatory strike on a U.S. base in Qatar resulted in no casualties. The Dow, S &P and Nasdaq all jumping about a percent. Crude and Brent both settling more than 7 percent lower. Shares of Circle Internet Group and fintech firm Fiserv hired today after Fiserv announced it will launch a stable coin relying on Circle's infrastructure. Shares of Circle now up 750 percent. That's all. Since its IPO earlier this month. Well, Well, Novo Nordisk down 5.5 % for its worst day in over two months, despite giving positive updates on its next-gen weight loss drugs at this year's ADA scientific sessions.

27:09The company also announcing an end to its direct-to-consumer partnership with Hims & Hers Health, sending Hims & Hers stock down 34%, its worst day on record. Angelica Peoples has got all the details. Angelica. Yeah, Melissa, really, ADA was not a great meeting for Novo. Now, going into the weekend, we knew that its next closest weight loss shot, Cagre Sema, produced similar weight loss to Lily's Zepound. And we know that Kagari Sama comes with slightly more side effects after this weekend. And we also learned more about Novo's shot, another one in the pipeline, Amy Creighton. And that showed promising weight loss, but concerning rates of side effects in a small early trial.

27:47They are advancing it, but there's now some more questions there. And then this morning, like you mentioned, Novo announcing that it's ending its collaboration with Hims and Hers to sell discounted Magovi on its website. And that's just one month into this partnership because of HIMSS's, quote, deceptive promotion and selling of illegitimate knockoff versions of Wagovi that put patient safety at risk. Now, HIMSS CEO Andrew Dudum firing back, saying that Novo, quote, increasingly pressured us to control clinical standards and steer patients to Wagovi, regardless of whether it was clinically best for patients.

28:19And HIMSS will continue to sell compounded GLP-1s and the brand name Wagovi, just not at that discounted cash price that they were getting from NovoCare. A Novo executive telling me that they expected HIMSS would eventually pivot away from compounded drugs over time, and then HIMSS pointing me to a statement, statements that they've made in the past, that they never planned to do that. So a really messy breakup here, Melissa. All right, Angelica, thank you, Angelica Peebles. Amgen, by the way, also dropping almost 6 % today after disappointing results for its once-monthly weight loss shot, Maritide.

28:49Patients without type 2 diabetes losing an average of 20 % of their body weight after one year. But the company reporting a high rate of side effects and discontinuations. It plans to adjust its dosing schedule in a phase 3 trial. For more on the obesity drug race, Jared Holes joins us here on set. He's a health care sector strategist at Mizuho. Jared, great to have you with us. Novo seems to be getting punished repeatedly for disappointing Cagrosemma data. And at the same time, we also got, you know, the disappointment from Anjen. But also positive news out of Eli Lilly when it comes to the oral candidate, which has a safe and clean liver profile.

29:27And then also the injectable amylin, which gives you weight loss with less muscle mass loss. So it makes it look like Eli Lilly is a king of the heap here. I think so. I mean, I think that's the takeaway from this weekend. You know, we all kind of went into it trying to ascertain whether there were, you know, different disparities in the market that we could kind of glean from from a data standpoint. It just doesn't look like anyone's even close to Lilly at this point. I mean, Novo is the second best, I guess, because they've been on the market the longest and they have 33 percent of the market.

29:59But based on the oral data from Lilly looking pretty clean and everything else in the pipeline, I think it's Lilly and then everybody else. So for Cargursema, how much do you just sort of write down that pipeline? Or is there still hope they will produce great, you know, the promised 25 percent weight loss in a later trial? I just don't know who's looking for 25 percent weight loss. That is like a 22 or something. Exactly. Like when you when you look at the difference between the weight loss statistics, I'm really not sure anyone is seeking that out other than people who are just definitively obese beyond kind of a normal 30 BMI.

30:35Someone much higher might want to go for something like that. Last time Jared was on, I asked him if Nova was out of the woods. He said, no, the stock is down 10 percent since. Well done by you. So here it's pivot to Amgen. Even if you back out this business for them, it's a company with a tremendous pipeline trading now maybe 12 and a half times next year's numbers. My question is, is the stock just too cheap here, despite this news that Mel just talked about? Yeah, I don't think it's cheap at all. I mean, pharma multiples have come down. The average is right around 10, I want to say. And they have a massive cliff, too.

31:07I mean, we always talk about Merck and Bristol. But over 50 % of their revenue goes away by the end of the decade or shortly after, in addition to those other peers. So I'm not really sure 12, 13 times is actually cheap. I think on a historic basis, for sure. And we talk about this a lot, relative versus absolute. But I would rather wait for Amgen to come in because all the other peers have sold off tremendously. This one is kind of hung in there. So I guess that that gets me into the biotech discussion versus traditional pharma. I mean, biotech actually has had a pretty decent run. It's been under some pressure, but there have been performance.

31:39And there is some sense that there's there are more catalysts to M &A and whatnot. So for a lot of investors not buying a particular name, but buying either XBI or IBB. I mean, just some thoughts on that, because it was it was a storm. It was a winter storm for a long time. And it feels like the environment's changed. Yeah, Tim, I think that's right. don't love biotech by any means. I think we still have a lot of things to kind of clean up. But when we consider, you know, just the revenue degradation at the pharma level and what these biotechs offer, there must be more M &A. Even if we don't believe that the assets that are out there are that superior to what, you know, pharma may have in its pipeline, there needs to be some sort of, you know, appreciation that we're going to see more deals.

32:21And big pharma, I mean, a lot of these guys need to do something. They must. I think almost all of them have to do something. I mean, even Pfizer, that's done six deals since the pandemic, has spent$60 billion, is on record saying that they're looking for more assets potentially in this obesity area. And last question on Amgen, going back to that stock, is today's decline, does it basically wipe out the potential of merit? I mean, they are going to launch new studies to look at sleep apnea as well as cardio and the impact there. So is there hope for this as a commercial drug or is that just hope?

32:53I mean, I wouldn't assign too much hope to it. Again, like the market, I don't believe, is demanding another modality. Like, do we need a monthly injection? It would be great if the data were better. But I don't really think patients are asking for it. I think the weeklies are very good. The data from Lilly is good. And then next year, we're going to have an oral. So unless the side effect profile changes with this new dosing that they're working on, I'm not really sure there's much value here. Not to say that there isn't in the models. I think we'll have to see over the next six to 12 months what, you know, the valuation looks like as analysts adjust their numbers.

33:26Right. Jared, great to see you. Thank you. Thank you. Jared Holtz. All right, Tim, you bought Novo thinking that it was too cheap. Do you regret it or? No, I don't regret it at all. I mean, I'd like to see better price action, but this this type of response to the to these announcements doesn't surprise me. I still think the first of all, the price kind of elasticity dynamic of where you're going to see more supply and where there is sensitivity there. The GLP market is probably going to double between now and 2030. And even if they lose 20 points of market share, their sales are going to double by 2030.

33:57So I just think this is the largest stock in Europe. It's a stock that I think people should own. And it's it's been less about a valuation call than I think the stock's been overly punished for that same conversation we had. Some of the results in terms of percentage of weight loss, I think, are overly scrutinized. Julie? Yeah, I think it's a really difficult situation where this company was not really set up for the success that it enjoyed. And I think you really see that in the management, the shakeup that we're seeing. It makes it really hard to feel super confident that directionally they're where they need to be.

34:31I agree at a base level that for them, they should be where they need to be in terms of having GLP-1s being part of that exploding growth that I think we'll continue to see, right? It's endless. But I really do wonder what the pricing dynamic is going to look like. And so you could say that there would be two or three times as many people on GLP-1s in five years. But if the price is cut by only 10 % of that, it really changes the dynamics for them. We had the CEO of Innsmed on, I think it was June 11th, William Lewis. The stock, I think, closed around 94. Had a ridiculous move that day, and we collectively said it probably wasn't over.

35:11And it's just built on that move. So there are places that work. I mean, despite this move, INSM, I still think goes higher from here. Coming up, a robo-taxi rally. Shares of Tesla charging higher after the EV maker rolled out its latest tech in Texas. Details from the launch and when you can expect to see driverless cars on your streets. when Fast Money returns.

35:40Welcome back to Fast Money. FedEx shares jumping 2 % today. The transport giant reports quarterly results after the bell tomorrow. The company also saying goodbye to its founder and longtime CEO Fred Smith, who passed away over the weekend at the age of 80. He's been on the network many times. Yeah. Fred, great guy. In terms of earnings, obviously, this is a bellwether for lots of things, economic indicator. Dan, you pointed this out in the call. Yeah, I think the earnings this week are so interesting. There's little bits and pieces. We have Micron. Obviously, we have Nike. And this one in particular, you know, you hear headlines.

36:12You saw the volatility that we've seen in the airlines just over the last few weeks or so in and around this geopolitical situation. So, obviously, a company like this has a mulligan, right? The volatility that you see in oil, the volatility that you see, you know, about trade. I mean, the list goes on and on. And so I think if it's the sort of thing where they actually can materially guide up and make investors feel a little bit better about this past year, I think it works on a whole host of levels. We just traded down to the third point of a six-year uptrend line starting in 2019 when this stock was probably$125.

36:44It has not traded well. I mean, I've tried to make a case on valuation most of the time wrong because it's dirt cheap. But I actually think this is a quarter you can be long into the numbers for. I do, too. I think it's a case where it's not about valuation because it's very cheap. And I think it's a case where there is some cyclicality here that can be bought. So I'll just get a drink of water. Well, just really quickly, because you're a little verklempt. The fact that the three of us like this thing, you might want to go the other way. I'm just saying. Can I just say one thing? Mrs. Seymour is watching right now, Tim's mom, who's lovely.

37:18And she's concerned about me. And she reached out to her son. And Tim's making fun of me, and she knows that her son was raised better than that. So thank you, Mrs. Seymour. She's a caring woman, and thanks for tuning in, Mom. I didn't actually know that you were lactose intolerant. I don't give you all my advice. But maybe not lactose. Coming up, Tesla's new Texas Tech details from the company's robo-taxi rollout and the big reaction, the stock. That's next. More Fast Money in 2.

37:54Welcome back to Fast Money. Tesla shares surging to kick off the week after the EV maker finally rolled out its robo-taxi service in Austin, Texas this weekend. Some of the vehicles were autonomous, while others had in-person drivers or remote monitors. But Sunday's invite-only debut marks the first step toward fulfilling a huge technological promise. Let's bring in Fast Money friend and Deepwater Asset Management Managing Director, Gene Munster, for more. Gene, great to have you with us. Hello. Was it worth 8 %? I mean, there's a guy sitting in the front seat. It was a very limited amount of Austin, Texas.

38:29And the only people who got rides were stock devotees and social media influencers. I think the answer, Melissa, is yes, it is. And stick with me here is that if we look at just today's event, it doesn't add up to that 8 % move. But we put in the context of what's happened over the past five years and seven years. And as somebody who believes in everything they're building, this comment is going to seem harsh. But this company has largely overpromised and undelivered on these big milestones. And so when the fact that they got it off and, well, it was limited, I think is an encouragement that they are moving towards the right direction.

39:08And the other piece about that 8 % move is this direction is not a small direction in terms of the impact that it could have to the model. I mean, it could fundamentally change the profit picture. I mean, the vast majority of this company's income could come from autonomous services, whether it's FSD or RoboTax or Optimus. And so in that context, and we're still at a$1.1 trillion market cap, it still feels like there's room to go if you believe in that vision. And so I see this is an appropriate move to the stock today. Gene, at what point do you think that contribution actually starts to happen for this stock?

39:46because if you look at the EV business, it couldn't be worse. It's literally at the worst spot that it's ever been if you go back a decade or so. So to believe that it's worth a trillion on its way to two or three, you have to believe in sooner than later that there's going to be a material contribution. And I just can't imagine that the margins for the first couple of years are going to be any good. You have to assume they're going to be losing money on this sort of trade. So I'm just curious thoughts there. On the maybe start with the second piece of that on the losing money, a different obviously setup versus what's going on with Waymo and that hundred thousand plus per vehicle this is an asset light approach they're funding the initial vehicles probably for the next year but most of this is going to be funded so I think that this business could be profitable probably within a year or two albeit the revenue is going to be pretty modest too which gets to the first point of like when does this actually you know we've been waiting and waiting and this was a big step forward but when is it actually going to be impacting the model it probably isn't for 2030 and to put some context around like how what potentially could be the impact by 2030 is that if they're on a path by 2030 to get to 70 % share of the right market actually in 2030 if they hit like a 30 or 40 % share of that market it's going to basically double their operating income so this is still way out there and and then how does that jive if we're still talking five years out there how does that jive with my feeling that this is a justified move and I think the answer is that yes it's five years out there but it's an undeniable truth is that this market is going to be fundamentally changed and it's a big market 90 billion dollars here in the US alone and it's really going to come down to Waymo and Tesla and Uber and and Lyft are largely going to be irrelevant in that future and so I think that's the piece that nugget that carrot that's out there still is not going to go away despite what I agree is going to be a really this is gonna be an ugly year on their their car business.

41:40Gene great to have you with us. Thank you. Thank you. Gene Munster, Deepwater. Guy. Hundreds of thousands, if not a million self-driving Teslas by the end of 2026, I think is what Elon Musk said. And maybe there's some existential risk to Uber. I just don't think that's it. Uber sold off on these headlines before. I think you own Uber on the back of this. All right. Up next, final trades.

42:11final trade time julie beal you know i always think of the guys on the panel as solid and reliable and so is fact that especially after the most recent earnings this panel uh tim well guy my my mom doesn't think i'm selfish my mom has said you've been mean to guy today and then she said the banks guy and the little heart next to it. So, you know, but I love GDX, by the way, GDX. Dan. Yeah, I agree with the facts that's underperformed this year, but probably that guidance should be encouraging. Lulu, Tim's Lulu, probably near a clean up guy. Well, I'd like to be long Mr. and Mrs. Seymour if I could.

42:46But in addition to that, let her see, Melissa Lee. Thank you for watching Fast Money. See you back here tomorrow at 5 for more Fast Mad Money with Jim Cramer. Starts right now.

42:59All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:33To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.

From the publisher

Crude oil sliding after Iran’s strike on a U.S. base in Qatar. The energy impact, and how the broader markets are reacting. Plus The next move for Novo Nordisk, as the pharma company cuts ties with Hims & Hers. What it means for the weight loss drug space, and how their latest trial data is hitting the stock.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Oil Drops As Iran Responds… Plus Novo Nordisk Cuts Ties With Hims & Hers 6/23/25CNBC's "Fast Money" · 44 min
Listen in VO